Flagship Ventures Fund IV General Partner LLC's Net Worth

$4.97 Billion

Who is Flagship Ventures Fund IV General Partner LLC?

Flagship Ventures Fund IV General Partner LLC has an estimated net worth of $4.97 Billion. This is based on reported shares across multiple companies, which include Moderna, Inc., Kaleido Biosciences, Inc., Seres Therapeutics, Inc., Editas Medicine, Inc., TransMedics Group, Inc., Rubius Therapeutics, Inc., Syros Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., T2 Biosystems, Inc., Axcella Health Inc., and Evelo Biosciences, Inc..

SEC CIK

Flagship Ventures Fund IV General Partner LLC's CIK is 0001508051

Past Insider Trading and Trends

2018 was Flagship Ventures Fund IV General Partner LLC's most active year for acquiring shares with 20 total transactions. Flagship Ventures Fund IV General Partner LLC's most active month to acquire stocks was the month of April. 2016 was Flagship Ventures Fund IV General Partner LLC's most active year for disposing of shares, totalling 47 transactions. Flagship Ventures Fund IV General Partner LLC's most active month to dispose stocks was the month of April. 2022 saw Flagship Ventures Fund IV General Partner LLC paying a total of $69,099,363.15 for 44,100,390 shares, this is the most they've acquired in one year. In 2020 Flagship Ventures Fund IV General Partner LLC cashed out on 32,241,407 shares for a total of $68,219,276.30, their largest year based on trade value.